1. Atorvastatin improves ovarian function and follicular reserve in rats with premature ovarian insufficiency.
- Author
-
Notghi P, Mehranjani MS, and Shariatzadeh SMA
- Subjects
- Female, Animals, Rats, Vascular Endothelial Growth Factor A metabolism, Vascular Endothelial Growth Factor A blood, Vascular Endothelial Growth Factor A genetics, Malondialdehyde metabolism, Malondialdehyde blood, Estradiol blood, Follicle Stimulating Hormone blood, Anti-Mullerian Hormone blood, Antioxidants pharmacology, Ovarian Reserve drug effects, Cyclophosphamide adverse effects, Proto-Oncogene Proteins c-bcl-2 metabolism, Proto-Oncogene Proteins c-bcl-2 genetics, Oxidative Stress drug effects, Tumor Necrosis Factor-alpha blood, Tumor Necrosis Factor-alpha metabolism, bcl-2-Associated X Protein metabolism, bcl-2-Associated X Protein genetics, Interleukin-6 blood, Interleukin-6 metabolism, Glutathione metabolism, Glutathione blood, Primary Ovarian Insufficiency drug therapy, Primary Ovarian Insufficiency chemically induced, Atorvastatin pharmacology, Rats, Wistar, Ovarian Follicle drug effects, Ovarian Follicle metabolism, Ovary drug effects, Ovary metabolism
- Abstract
Research Question: Can atorvastatin, with its antioxidant, anti-inflammatory and anti-apoptotic properties, improve ovarian function and follicular reserve in rats with cyclophosphamide-induced premature ovarian insufficiency (POI)?, Design: In this experimental study, 24 adult female Wistar rats were divided into four groups: control; POI; POI + atorvastatin; and atorvastatin. After treatment with atorvastatin, serum concentrations of total antioxidant capacity, glutathione, malondialdehyde, FSH, oestradiol, anti-Müllerian hormone, tumour necrosis factor-alpha and interleukin-6 were evaluated. Additionally, mRNA and protein expression of Bax, Bcl-2 and VEGF-A; number of follicles; and total volume of the ovary, and volumes of the cortex and medulla were examined., Results: The results showed that serum concentrations of total antioxidant capacity (P < 0.001), glutathione, oestradiol and anti-Müllerian hormone (P < 0.05); mRNA and protein expression of Bcl-2 and VEGF-A (P < 0.05); number of primordial and primary follicles (P < 0.001), and preantral and antral follicles (P < 0.01); and total volume of the ovary, and volume of the cortex (P < 0.05) increased significantly in the POI + atorvastatin group compared with the POI group. Serum concentrations of malondialdehyde, FSH, tumour necrosis factor-alpha and interleukin-6; and mRNA and protein expression of Bax decreased significantly in the POI + atorvastatin group compared with the POI group (P < 0.05)., Conclusions: Atorvastatin reduces the detrimental effects of cyclophosphamide in the POI model significantly by reducing oxidative stress and pro-inflammatory cytokines; regulating the expression of Bax, Bcl-2 and VEGF-A; and improving ovarian function and follicular reserve., (Copyright © 2024 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF